ULURU, a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products announced that it has signed a licensing and supply agreement with Jiangxi Aiqilin Pharmaceuticals for the marketing of Altrazeal in China, including Hong Kong, Macau and Taiwan. Altrazeal is a wound treatment technology developed by ULURU.

Under the terms of the licensing and supply agreement ULURU will receive an upfront licensing payment, milestone payments based on regulatory approvals and sales performance and a royalty on product sales. Aiqilin has also been granted certain manufacturing rights. The license agreement covers Altrazeal, Altrazeal Silver and Altrazeal Collagen.

Commenting on the agreement, Mr Chunhua Hu, President and CEO of Aiqilin, stated, "There are more than 20 million wound patients annually in China. The wound care market segment is a rapidly growing area in the Chinese market. Aiqilin is well connected and has strong support from the clinical experts and researchers, extensive marketing and sales channels to effectively promote, sell and further develop Altrazeal in China."

China is rapidly becoming a major health care market, where it is projected that sales will grow from $25 billion in 2009 to $220 billion in 2020, making it the second largest market in the world. It is anticipated that Altrazeal could be approved by the Chinese regulatory authorities in early 2011.

Mr Kerry Gray, President and CEO of ULURU, stated; "China is an extremely important market where we anticipate Altrazeal can rapidly establish a significant market presence. This represents the first step in our plan to have Altrazeal marketed globally and provides external commercial validation of Altrazeal and our proposed product line extensions."